Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-09-18
2007-09-18
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S361100, C548S362500
Reexamination Certificate
active
10493601
ABSTRACT:
A compound represented by the general formula I: I wherein R1 represents hydrogen, etc. R2represents NHSO2R3, etc., provided that R3represents C1-6alkyl, etc. R5represents hydrogen, etc. R6and R7may be the same or different and each independently represents hydrogen, etc. X represents oxygen, etc. Y represents oxygen, etc. Z1to Z6each represents carbon, etc. n is an integer of 0 to 6 and ast1 indicates that the carbon atom is asymmetric, and *2, in the case where R5is not hydrogen, indicates that the carbon atom is asymmetric or a salt of the compound.
REFERENCES:
patent: 4378361 (1983-03-01), Schromm et al.
patent: 5767133 (1998-06-01), Dow et al.
patent: 5859044 (1999-01-01), Dow et al.
patent: 6037362 (2000-03-01), Miyoshi et al.
patent: 6172099 (2001-01-01), Miyoshi et al.
patent: 6495701 (2002-12-01), Matsubara et al.
patent: 6861444 (2005-03-01), Ikuta et al.
patent: 2003/0040538 (2003-02-01), Miyoshi et al.
patent: 2003/0191174 (2003-10-01), Ikuta et al.
patent: 2004/0102437 (2004-05-01), Takami et al.
patent: 2004/0138286 (2004-07-01), Imazaki et al.
patent: 24 29 253 (1974-06-01), None
patent: 26 51 572 (1977-06-01), None
patent: 0 008 653 (1980-03-01), None
patent: 0 023 385 (1981-02-01), None
patent: 0 171 702 (1986-02-01), None
patent: 0 455 006 (1991-04-01), None
patent: 659 737 (1995-06-01), None
patent: 1 174 425 (2000-03-01), None
patent: 1 565 080 (1976-11-01), None
patent: 55-53262 (1980-04-01), None
patent: 58-41860 (1983-03-01), None
patent: 8-165276 (1996-06-01), None
patent: WO94/29290 (1994-12-01), None
patent: WO95/29159 (1995-11-01), None
patent: WO96/35670 (1996-11-01), None
patent: WO97/25311 (1997-07-01), None
patent: WO9901431 (1999-01-01), None
patent: WO 00/35890 (2000-06-01), None
patent: WO 00/59287 (2000-10-01), None
patent: WO 00/59885 (2000-10-01), None
patent: WO 01/56988 (2001-08-01), None
patent: WO 01/83451 (2001-11-01), None
patent: WO 01/83452 (2001-11-01), None
patent: WO 01/83453 (2001-11-01), None
patent: WO 02/100833 (2002-12-01), None
Arch et al., “Atypical B-adrenoceptor on brown adipocytes as target for anti-obesity drugs”, Nature, vol. 309, May 1984, pp. 163-165.
Arch et al., “Prospects for B3-adrenoceptor agonists in the treatment of obesity and diabetes”, international Journal of Obesity, 1996, vol. 20, pp. 191-199.
Largis et al., “Antidiabetic and Antiobesity Effects of a Highly Selective B3-Adrenoceptor Agonist (CL 316,243)”, Drug Development Research, 1994, vol. 32, pp. 69-76.
Fisher et al., “A Selective Human B3Adrenergic Receptor Agonist Increases Metabolic Rate in Rhesus Monkeys”, J. Clin. Invest., 1998, vol. 101, pp. 2387-2393.
Fujimura et al., “Expression and Possible Functional Role of the B3-Adrenoceptor in Human and Rat Detrusor Muscle”, The Journal of Urology, 1999, vol. 161, pp. 680-685.
Takeda et al., “Evidence for B3-Adrenoceptor Subtypes in Relaxation of the Human Urinary Bladder Detrusor: Analysis by Molecular Biological and Pharmacological Methods”, The Journal of Pharmacology and Experimental Therapeutics, 1999, vol. 288, pp. 1367-1373.
Cantello et al., “BRL 35135”, Drugs of the Future, 1991, vol. 16, pp. 797-800.
Humber et al., “Disodium . . . A Potent B-Adreneric Agonist Virtually Specific for B3Receptors. A Promising Antidiabetic and Antiobesity Agent”, J. Med. Chem, 1992, vol. 35, pp. 3081-3084.
Miyoshi Shiro
Ogawa Kohei
Asahi Kasei Pharma Corporation
Chung Susannah L.
Saeed Kamal A.
LandOfFree
Indazole compounds as β3 adrenoceptor agonist does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indazole compounds as β3 adrenoceptor agonist, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indazole compounds as β3 adrenoceptor agonist will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3761764